The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care.

The skin serves as the body's primary defense against harmful microorganisms, toxins, and physical damage. However, severe ...

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

A major challenge in self-powered wearable sensors for health care monitoring is distinguishing different signals when they occur at the same time. Researchers addressed this issue by uncovering a new ...

A major challenge in self-powered wearable sensors for health care monitoring is distinguishing different signals when they ...

The South Carolina Burn Center at the Medical University of South Carolina, the Zucker Institute for Innovation Commercialization, and Chitozan Health are hoping a new collaboration will revolutionize ...